Current Report Filing (8-k)
October 06 2014 - 8:15AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: October 1, 2014
(Date of earliest event reported)
MusclePharm Corporation
(Exact name of registrant as specified in
its charter)
NEVADA |
|
000-53166 |
|
77-0664193 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
4721 Ironton Street, Building A
Denver, Colorado 80239
(Address of principal executive offices)
(Zip Code)
(303) 396-6100
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
On October 1, 2014, MusclePharm Corporation
(the “Company”) submitted an Option Exercise Notice (the “Notice”) to CoCrystal Pharma, Inc. (f/k/a BioZone
Pharmaceuticals, Inc., hereinafter called “CoCrystal”) and a third party escrow agent (the “Escrow Agent”)
pursuant to requirements of that certain Asset Purchase Agreement entered into by and between the Company, CoCrystal, and certain
of CoCystal’s subsidiaries (the “APA”), which was disclosed in the Company’s Current Report on Form 8-K
filed with the Securities and Exchange Commission on January 6, 2014.
Pursuant to the Notice, as permitted by
to the APA, the Company purchased 250,000 shares of the Company’s common stock, which were being held in escrow, for an aggregate
purchase price of $2,500,000, which was wired to the Escrow Agent.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
MUSCLEPHARM CORPORATION |
|
|
|
Dated: October 6, 2014 |
|
|
|
By: |
/s/ Brad J. Pyatt |
|
Name: |
Brad J. Pyatt |
|
Title: |
Chief Executive Officer and President |
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Apr 2023 to Apr 2024